Ken Griffin Organogenesis Holdings Inc. Call Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$2.28 - $3.03 $15,047 - $19,998	-6,600 Reduced 63.46%	3,800 $10,000
Q1 2024 May 15, 2024	SELL	$2.61 - $4.49 $29,754 - $51,186	-11,400 Reduced 52.29%	10,400 $29,000
Q4 2023 Feb 14, 2024	BUY	$1.97 - $4.21 $35,854 - $76,622	18,200 Added 505.56%	21,800 $89,000
Q3 2023 Nov 14, 2023	SELL	$2.34 - $4.43 $7,020 - $13,290	-3,000 Reduced 45.45%	3,600 $11,000
Q2 2023 Aug 14, 2023	SELL	$1.9 - $4.3 $2,090 - $4,730	-1,100 Reduced 14.29%	6,600 $21,000
Q1 2023 May 15, 2023	SELL	$1.89 - $2.93 $3,780 - $5,860	-2,000 Reduced 20.62%	7,700 $16,000
Q4 2022 Feb 14, 2023	SELL	$2.48 - $3.43 $23,560 - $32,585	-9,500 Reduced 49.48%	9,700 $26,000
Q3 2022 Nov 14, 2022	BUY	$3.14 - $6.43 $19,468 - $39,866	6,200 Added 47.69%	19,200 $62,000

117

63.2M

25K

23.2K

Ticker ORGO
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 130,888,000
Market Cap $530M
Description
Organogenesis Holdings Inc., a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokin...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.